secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2021-11-23T23:59:59+00:00
Accession:  0001613103-21-000058
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q2 FY2022 revenue $7.85B (+2% organic), non-GAAP EPS $1.32; lowers FY revenue growth view
--------------------------------------------------------------------------------

- Revenue $7.847B (+3% reported, +2% organic); GAAP EPS $0.97, non-GAAP EPS $1.32.
- Organic growth: Cardiovascular +3%, Medical Surgical flat (ex-ventilators +6%), Neuroscience +3%, Diabetes +1%.
- Lowers FY22 organic revenue growth guidance to 7-8% from ~9% due to COVID-19 and labor shortages.
- Reiterates FY22 non-GAAP EPS guidance $5.65-$5.75; FX revenue benefit reduced to $0-50M from $100-200M.
- Diabetes pump sales grew high-teens US, low-twenties international; CGM sales low-single digits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310321000058/0001613103-21-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310321000058/mdt-20211123.htm
  HTML page:      https://secwatch.observer/filing/0001613103-21-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer